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Abstract
Objective. To examine the reliability (stability) and sensitivity of the Bristol Rheumatoid Arthritis Fatigue
scales (BRAFs) and patient-reported outcome measures (PROMs) developed to capture the fatigue
experience. The Multi-Dimensional Questionnaire (BRAF-MDQ) has a global score and four subscales
(Physical Fatigue, Living with Fatigue, Cognitive Fatigue and Emotional Fatigue), while three numerical
rating scales (BRAF-NRS) measure fatigue Severity, Effect and Coping.
Methods. RA patients completed the BRAFs plus comparator PROMs. Reliability (study 1): 50 patients
completed questionnaires twice. A same-day testretest interval (minimum 60 min) ensured both
time points related to the same 7 days, minimizing the capture of fatigue fluctuations. Reliability (study
2): 50 patients completed the same procedure with a re-worded BRAF-NRS Coping. Sensitivity to change
(study 3): 42 patients being given clinically a single high dose of i.m. glucocorticoids completed ques-
tionnaires at weeks 0 and 2.
Results. The BRAF-MDQ, its subscales and the BRAF-NRS showed very strong reliability (r= 0.820.95).
BRAF-NRS Coping had lower moderate reliability in both wording formats (r= 0.62, 0.60). The BRAF-MDQ,
its subscales and the BRAF-NRS Severity and Effect were sensitive to change, with effect sizes (ESs)
of 0.330.56. As hypothesized, the BRF-NRS Coping was not responsive to the pharmaceutical interven-
tion (ES 0.05). Preliminary exploration suggests a minimum clinically important difference of 17.5% for
improvement and 6.1% for fatigue worsening.
Conclusion. The BRAF scales show good reliability and sensitivity to change. The lack of BRAF-NRS
Coping responsiveness to medication supports the theory that coping with fatigue is a concept distinct
from severity and effect that is worth measuring separately.
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Introduction
Fatigue in RA is probably caused by a dynamic interaction
of clinical factors (inflammation, pain, disability) and psy-
chosocial issues (coping, mood, illness beliefs), which will
vary between and within individuals and over time [14].
Fatigue affects up to 70% of patients with RA and
is experienced as overwhelming, unpredictable and
challenging for them to manage [58]. The acknowledge-
ment of fatigue as a symptom that is important to patients
has resulted in international agreement that fatigue should
be measured in all RA trials alongside the core set [9].
Consequently, when a review of existing instruments
found that none adequately captured RA fatigue from
the patient perspective [10], the Bristol Rheumatoid
Arthritis Fatigue scales (BRAFs) were developed in collab-
oration with patients [11, 12]. The Multi-Dimensional
Questionnaire (BRAF-MDQ) is a 20-item questionnaire
giving an overall global score and four subscale scores
reflecting physical fatigue, living with fatigue, cognitive
fatigue and emotional fatigue. In addition, three single-
item scales measure fatigue severity, effect and coping
using numerical rating scales (BRAF-NRS). Face and con-
tent validity of the BRAFs was established in a series of
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studies including qualitative interviews to identify import-
ant concepts, focus groups to draft items and cognitive
interviewing to examine the language and understanding
of the proposed questions [11]. Factor analysis in a cohort
of 229 patients identified 20 items out of 45 draft items
that provided four internally consistent subscales, along
with construct and criterion validity [12]. The BRAFs have
been translated into 34 languages [13]. The recommended
methodology of iterative backward and forward transla-
tions, independent review and harmonization meetings
with the developers was used, and the translated BRAFs
were subsequently pilot tested with patients using cogni-
tive interviewing to ensure the comprehension of the
individual questions [1416].
It is essential that patient-reported outcomes (PROMs)
are both reliable (stable) and sensitive (responsive).
Reliability is when an instrument yields similar results on
repeated applications when the concept being measured
has not changed [1720]. There is no consensus about the
length of time between the two completions, but it needs
to be sufficiently long that participants cannot simply
recall their previous answers, yet short enough to mini-
mize the possibility that the concept being measured
has meaningfully changed. Thus the key factor is the sta-
bility of the construct being measured [1720]. In the case
of RA fatigue, patients report that it can occur without
warning, to the extent that they suddenly have to stop
their activities and sit or lie down [68]. Such unpredict-
ability restricts the concept of stability in RA fatigue to a
narrow time frame.
Sensitivity to change is when a PROM is responsive or
able to detect meaningful change over time in the concept
being measured, for example after an effective interven-
tion [1720]. While there are currently no pharmacological
interventions offered purely for RA fatigue, for some pa-
tients fatigue is a feature of inflammatory flares, and there-
fore the symptom might respond to medications designed
to reduce inflammation (e.g. i.m. glucocorticoids), provid-
ing a useful scenario in which to test the sensitivity of a
fatigue scale. However, as this does not attempt to alter
coping with fatigue, we hypothesized that the BRAF-NRS
Coping would not be sensitive to such an intervention.
While a PROM might reflect change after an intervention,
this does not necessarily indicate the change is important
to the patient. A minimum clinically important difference
(MCID) is the smallest amount of change in a particular
PROM that reflects a meaningful change for the patient
[21, 22]. MCID can be calculated by comparing change
in the PROM with change determined by either a transi-
tion question that asks patients whether they consider
their symptom to be better, the same or worse [22] or
with change in a related (surrogate) concept such as
pain [21]. Previous research using surrogate anchors in
multiple studies, followed by consensus techniques to re-
solve uncertainty, suggest an MCID of 1 for improve-
ment on a visual analogue scale (VAS) of fatigue of 010
[21]. Another study, this time using a 5-point fatigue tran-
sition question (much worsened to much better) as an
anchor, gave an MCID for fatigue of 0.82 to 1.12 for
improved fatigue and a larger +1.13 to +1.26 for worsened
fatigue on a 010 VAS [22]. The aim of these three studies
was therefore to examine the reliability and sensitivity to




Consecutive patients were recruited from the rheumatol-
ogy outpatient department at a single teaching hospital in
the Southwest of England. Inclusion criteria for all three
studies were a confirmed diagnosis of RA [23], with no
other co-morbidities in which fatigue is a common feature
(e.g. SLE, multiple sclerosis or cancer). In addition, pa-
tients recruited for study 3 (sensitivity to change) had to
have been prescribed a single high dose of i.m. gluco-
corticoids for clinical reasons during their appointment.
Ethics approval for the studies was granted by the North
Somerset and South Bristol Research Ethics Committee
(06/Q2006/104) and written consent was obtained.
Measures
Demographic data were collected on age, sex, disease
duration and disability (HAQ) [24] at baseline. The ques-
tionnaire packs used in all three studies comprised the
BRAF and comparator fatigue scales. All BRAF scales
ask about fatigue over the last 7 days. The BRAF-MDQ
has 20 items: item 1 (severity) response is 010, item 2
(number of days) is 07 and item 3 (episode length) is
<1 h, several hours or all day, scored 02, while items
420 have response options of not at all, a little, quite a
bit and very much (scored 03). All 20-item scores are
totalled for the global fatigue score (range 070), while
four subscales are created for physical fatigue (items
14, range 022), living with fatigue (items 511, range
021), cognitive fatigue (items 1216, range 015) and
emotional fatigue (items 1720, range 012), with higher
scores representing worse fatigue [12]. Missing data
were handled according to the BRAF scoring instructions
[13]. The BRAF-NRS Severity asks the average level of
fatigue (anchors: no fatigue, totally exhausted, 010),
BRAF-NRS Effect asks about the effect fatigue has had
on your life (anchors: no effect, a great deal of effect,
010) and BRAF-NRS Coping asks how well you have
coped with fatigue (anchors: not at all well, very well,
010), thus the reversed BRAF-NRS Coping anchors
mean high scores reflect better coping. Following analysis
of reliability study 1, the coping anchors were further clar-
ified to read not coping at all well and coping very well, and
the study repeated with a fresh cohort of participants (re-
liability study 2).
The four comparator fatigue PROMs for all three studies
were the Functional Assessment of Chronic Illness
Therapy Fatigue Scale (FACIT-F) [25], the Multi-dimen-
sional Assessment of Fatigue (MAF) [26], the Profile of
Mood States (POMS) [27] and the Short Form-36 Health
Survey Vitality subscale (SF-36 VT) [28]. Pain and patient
global opinion of disease were measured using a 10-cm
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VAS [29, 30]. Two versions of the questionnaire packs
(A and B) contained the PROMs in different orders, to
try and minimize recall and order bias. In all studies, alter-
nate patients were given version A (or B) at baseline and
the opposite version at their second time point.
Procedure
Reliability study 1
The BRAFs measure fatigue over the last 7 days, and as
RA fatigue has an inherent variability [68], a long period
between assessments would risk capturing unpredictable
fatigue fluctuations or sudden onset of a new episode,
potentially altering the patient’s judgement of their fatigue
over the preceding week. Such data would reflect the
nature of the construct rather than the reliability of the
PROM. Patients therefore completed the first question-
naire pack [time 1 (T1)] on arrival at the clinic and the
second questionnaire pack [time 2 (T2)] the same day,
after a minimum of 60 min, ensuring that both question-
naire completions related to the same 7 days.
Reliability study 2
The BRAF-NRS Coping was reworded and the same
procedure repeated with a new cohort of patients.
Sensitivity study 3
A single high dose of i.m. glucocorticoids generally pro-
duces a rapid improvement in clinical status, such as a
reduction in swollen joints, pain, disability and fatigue
within a few days [31]. Patients who were prescribed a
single high dose of i.m. glucocorticoids as part of clinical
care during their appointment completed the first ques-
tionnaire pack (T1) in the clinic while waiting to have their
injection. The second pack (T2) was posted to the
patients’ homes 2 weeks later and returned in a prepaid
envelope. At T2, the questionnaire pack contained a tran-
sition question (Has your fatigue changed? Better/Same/
Worse), in order to provide pilot data for calculating the
MCID of the BRAFs.
Sample size
For reliability (studies 1 and 2), a comparison study esti-
mate of 50 complete data sets is needed to produce cor-
relation coefficients of50.4 as statistically significant with
a power of 82%. For sensitivity (study 3), 40 patients are
required to detect a fatigue effect size of 0.46 (shown in a
previous study of i.m. glucocorticoids) [31] with 80%
power (5% significance). Sample size for a Bland and
Altman plot and limits of agreement cannot be formally
calculated, but we estimated that 50 sets of data would
produce a plot that would be reasonably consistent and
easy to interpret.
Analysis
Reliability was assessed using Pearson’s correlation coef-
ficient to measure the strength of the association between
the two sets of scores. Previous guidelines on interpreting
Pearson’s correlation coefficients for the BRAFs were
used: considered weak at r= 0.30.49, moderate at
r= 0.50.74 and strong at 50.75 [32]. Correlation coeffi-
cients provide information on how the two sets of scores
vary together but does not assess measurement error,
therefore Bland and Altman plots were also used. This
method assumes the true score is likely to be represented
by the mean of the two scores, therefore each patient’s
difference between their two scores is plotted against this
mean, with 2 S.D. of the mean considered the limits of
agreement [33].
Sensitivity to change was examined using effect sizes
(mean change divided by baseline S.D.), with an effect size
of 0.2 considered to be small, 0.5 medium and50.8 large
[32]. This was compared with the effect sizes seen in other
fatigue PROMs. MCID was provisionally explored by using
the fatigue transition question as an anchor of worse,
same or better fatigue, and calculating the mean BRAF
change for each category (95% CI).
Results
Reliability study 1
Ninety consecutive patients were invited to take part in the
study: 57 accepted and 33 declined. Of those 57, 7 were
withdrawn from the study due to non-completion of the
questionnaires at one time point (defined as not returning
a completed questionnaire pack to the research team).
Fifty patients participated, with a range of disease dur-
ation, moderate pain and disability (Table 1) and moderate
fatigue (Table 2). There was a very strong correlation
between the T1 and T2 scores for the BRAFs: BRAF-
MDQ global (r= 0.95), each of the four BRAF-MDQ sub-
scales (r= 0.890.94), BRAF-NRS Severity (r= 0.92) and
BRAF-NRS Effect (r= 0.85) (Table 2). The BRAF-NRS
Coping results showed a lower but still moderate agree-
ment (r= 0.62).
Bland and Altman limits were relatively narrow, indicat-
ing good levels of agreement. The BRAF-MDQ global
score agreement was within 11 points (scale range 070,
observed values 470) (Fig. 1), the BRAF-MDQ subscales
were all within 5 points (Living with Fatigue, Cognitive
Fatigue and Emotional Fatigue scale ranges and observed
values 012, 015 and 021, respectively; Physical Fatigue
scale range 022, observed values 322) (Fig. 1). The
BRAF-NRS Severity and Effect scores were both within 3
points (scale ranges 010; observed values 010 for Effect
and 110 for Severity) (Table 3). The BRAF-NRS Coping
performed less strongly, with limits of agreement within 5
points of the 010 scale (observed values 010), therefore
the wording of the BRAF-NRS Coping was clarified by
adding cope to the anchors, and the study was repeated
with a fresh cohort of participants (study 2).
Reliability study 2
Eighty-three consecutive patients were invited to take part
in the study: 59 accepted and 24 declined. Of those 59, 9
were withdrawn from the study due to non-completion of
the questionnaires at one time point. Fifty patients parti-
cipated, with similar characteristics to those in study 1
(Tables 1 and 2). Study 1 findings were replicated, with
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very strong correlations for the T1 and T2 BRAF-MDQ
global and subscales, and BRAF-NRS Severity and
Effect (r= 0.840.93) (Table 2). BRAF-NRS Coping reliabil-
ity was unchanged (r= 0.60). Bland and Altman limits of
agreement were also replicated, with BRAF-MDQ global
scores within 12 points, BRAF-MDQ subscales within 6
points and BRAF-NRS Severity and Effect within 3
points. The limits of agreement for BRAF-NRS Coping
were again within 5 points.
Sensitivity study 3
Seventy patients were invited to take part in the study: 64
accepted and 6 declined. Of those 64, 22 were withdrawn
from the study: 16 participants due to non-completion of
the questionnaires at one time point and 6 participants
due to not meeting the inclusion criteria of a confirmed
diagnosis of RA [23]. Forty-two patients participated, with
moderate disease duration and disability but high fatigue
and pain levels (Tables 1 and 3). The BRAF-MDQ global
scale was sensitive to change (ES 0.56), as were the four
subscales (ES 0.330.54) and the BRAF-NRS Severity and
Effect (ES 0.46, 0.47) (Table 4). As hypothesized, the
BRAF-NRS Coping was not sensitive to change in this
pharmacological intervention (ES 0.05).
Using the transition question, ‘Has your fatigue chan-
ged?’, as an anchor, the mean (S.D.) change in the BRAF-
MDQ for the 14 patients who reported no change in their
fatigue was 2.42 (8.29), with a 95% CI of 7.43 to 2.58.
This means that any patient in whom the BRAF-MDQ score
improved by more than 7.43 will have reported an improve-
ment in their fatigue in response to therapy. This represents
17.5% of the pre-treatment value and provides an initial
estimate of MCID for improvement. Any patient whose
BRAF-MDQ score deteriorated by more than 2.58 will
have reported a worsening of their fatigue in response to
therapy. This represents 6.1% of the pre-treatment value
and provides an initial estimate of MCID for worsening.
The four comparator fatigue scales had similar reliability
and sensitivity to the BRAFs (Tables 2 and 3). However,
missing data meant that 12% of MAF and 10% of POMS
questionnaires could not be scored, compared with 3% of
TABLE 2 Correlation, reliability studies 1 and 2
Reliability study 1 (n= 50) Reliability study 2 (n= 50)
T1 T2 Corr T1 T2 Corr
mean (S.D.) mean (S.D.) r mean (S.D.) mean (S.D.) r
BRAF-MDQ
Global (070) 37.2 (16.8) 37.5 (17.3) 0.95 36.0 (17.8) 35.4 (17.4) 0.93
Physical (022) 14.8 (5.2) 15.1 (5.2) 0.94 14.3 (5.4) 14.5 (5.3) 0.93
Living (021) 9.5 (6.0) 9.7 (6.0) 0.89 9.6 (6.5) 9.4 (6.0) 0.89
Cognition (015) 6.8 (4.8) 6.9 (4.3) 0.89 6.3 (4.5) 6.0 (4.6) 0.89
Emotion (012) 6.1 (3.8) 5.9 (3.8) 0.92 5.3 (3.9) 5.5 (3.7) 0.84
BRAF-NRS
Severity (010) 6.2 (2.3) 6.3 (2.3) 0.92 5.9 (2.3) 6.0 (2.4) 0.92
Effect (010) 6.0 (2.6) 6.1 (2.6) 0.85 5.9 (2.8) 5.9 (2.7) 0.88
Coping (010)a 5.7 (2.9) 5.2 (2.9) 0.62 6.3 (2.5) 5.7 (2.5) 0.60
SF-36 VT (0100)a 33.4 (21.2) 37.4 (19.6) 0.61 35.9 (20.1) 36.8 (21.5) 0.76
FACIT-F (052)a 24.1 (11.5) 23.6 (11.4) 0.95 23 (11.1) 25.4 (10.2) 0.88
POMS (028) 16.0 (7.4) 15.9 (7.4) 0.90 15.6 (7.9) 15.6 (7.3) 0.93
MAF (150) 31.6 (10.1) 31.3 (9.6) 0.91 32.0 (8.1) 31.6 (9.2) 0.88
aHigher score indicates better outcome.
TABLE 1 Demographic and clinical data, studies 1, 2 and 3 at baseline
Reliability study 1 (n= 50) Reliability study 2 (n= 50) Sensitivity study 3 (n= 42)
Mean (S.D.) Range Mean (S.D.) Range Mean (S.D.) Range
Women, n (%) 36 (72) 34 (68) 34 (81)
Age, years 56.3 (12.8) 2576 55.8 (13.6) 2178 56.7 (12.6) 3076
Disease duration, years 13.4 (12.7) 0.560 8.9 (11.3) 0.250 10.7 (10.7) 0.0543
Disability (HAQ 03) 1.6 (0.8) 03 1.4 (0.9) 03 1.9 (0.7) 0.8753
Pain (VAS 0100) 54.9 (26.1) 898 51.5 (30.1) 196 70.8 (19.9) 2296
Patient global (VAS 0100) 46.7 (26.1) 796 46.6 (27.1) 295 58.2 (24.9) 395
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FACIT, 1% of the SF-36 VT and 0.5% of the BRAFs
(based on the percentage of questionnaires that could
not be scored due to missing data in the testretest reli-
ability studies, including time points 1 and 2).
Discussion
The BRAFs were rigorously developed with input from
patients. The process began with semi-structured
interviews with patients in which they identified their
experiences of fatigue and the language they used to
describe them [6]. These qualitative data were subse-
quently discussed with patients in focus groups, ensuring
that the concepts of fatigue captured the full experience.
This included different fatigue dimensions such as cog-
nitive fatigue and physical fatigue and also perceived
fatigue coping and effect. Once the BRAFs had been
drafted, patients’ understanding and interpretation of
FIG. 1 Limits of agreement for BRAF-MDQ and -NRS Severity, Effect and Coping.
Mean difference (central line) and limits of agreement (outer lines, at 2 S.D.) for the BRAF-MDQ and -NRS for Severity (S),
Effect (E) and Coping (C) measured at times T1 and T2. Coincident points slightly separated for clarity.
TABLE 3 Bland and Altman levels of agreement
Reliability study 1 (n= 50) Reliability study 2 (n= 50)
Mean difference 95% levels of agreement Mean difference 95% levels of agreement
BRAF-MDQ
Global (070) 0.36 11.1, 10.4 0.13 12.6, 12.3
Physical (022) 0.34 3.8, 3.1 0.40 4.1, 3.3
Living (021) 0.18 5.6, 5.3 0.2 5.5, 5.9
Cognition (015) 0.08 4.3, 4.1 0.26 3.9, 4.4
Emotion (012) 0.04 1.8, 1.7 0.16 4.5, 4.1
BRAF-NRS
Severity (010) 0.08 2.8, 2.6 0.14 1.9, 1.6
Effect (010) 0.24 2.7, 3.2 0.12 2.8, 2.5
Coping (010)a 0.5 4.5, 5.5 0.45 3.8, 4.7
SF-36 VT (0100)a 2.84 25, 30.7 0.41 29, 28.2
FACIT-F (052)a 0.17 7.2, 7.5 2.21 12.2, 7.7
POMS (028) 0.03 6.6, 6.6 0.47 4.8, 5.7
MAF (150) 0.45 7.8, 8.7 0.82 7.2, 8.8
aHigher scores indicate better outcome.
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the concepts, questions and response options were
explored during cognitive interviewing [11]. Data from
the current study show that the BRAFs are reliable
when the patient’s condition does not change, and
sensitive when it does, adding further to the validation
evidence. Strong reliability was shown, evidenced con-
sistently in two different cohorts of patients (studies 1
and 2). The choice of a short time frame (minimum 60
min between completions) was designed to accommo-
date the sudden and dramatic onset of fatigue reported
in the literature [68] and to allow patients to consider the
same 7-day period for both completions. The reliability of
the BRAF-NRS Coping was less strong, but adequate, at
r= 0.62, based on accepted levels for PROM validation
[17, 18]. It was postulated that this was due to the ab-
sence of the word cope in the anchor statements, as a
reminder of the question, but reliability was unchanged
when this wording was clarified (reliability study 2).
Another possibility is that presenting the BRAF-NRS
Coping as the third in a page of three NRSs and the
only one to be reverse-scored might have been unclear
for patients. However, during the design of the BRAFs,
patient focus groups expressed a strong consensus that
positive coping must be represented by a higher number
if it is to make sense to them [11]. Such patient involve-
ment in the clarity of wording during the development of
PROMs is recommended best practice [20]. A very simi-
lar coping scale has been used in a randomized con-
trolled trial (RCT) of cognitive behavioural therapy (CBT)
for fatigue self-management [34], the only difference
being in the lower anchor, which was ‘very poorly’ (com-
pared with the BRAF-NRS ‘not at all well’). In the RCT
this VAS was also reliable, being unchanged over 18
weeks in the control group [week 0 mean 6.0 (S.D. 2.3);
week 18 mean 5.98 (S.D. 2.5), n= 62] [34].
The BRAF scales showed sensitivity to change follow-
ing a single i.m. injection of high-dose glucocorticoids,
even though patients were not recruited with fatigue as
an inclusion criterion. As hypothesized, the BRAF-NRS
Coping did not reflect change after a pharmacological
intervention that was not designed to change coping
skills. This probably reflects a true state in the underlying
construct (i.e. coping with fatigue did not change) rather
than a lack of responsiveness in the BRAF-NRS Coping
item. This is supported by data from the RCT of CBT for
RA fatigue in which the previously described, almost iden-
tical coping VAS was used and was very responsive to an
intervention designed to improve fatigue coping skills (ES
0.79) [34].
The BRAF-NRS for Coping with fatigue therefore be-
haves differently from those for fatigue severity and
effect. Previous research has shown that a patient can
have a disconnect between the severity of fatigue, the
effect of fatigue and their perceived ability to cope with it
[12]. These findings are coherent with the theory of
coping as a distinct concept [35] that can be assessed
separately from symptom severity and effect. As coping
is conceptualized as a multidimensional construct [36], it
is possible that a multidimensional measure would be
able to detect changes in aspects of coping that
cannot be captured using a unidimensional instrument.
In the future, it could be useful to use a multidimensional
measure of coping with fatigue, particularly in relation to
psychosocial interventions aimed at enhancing coping
ability. The measurement of patient outcomes has trad-
itionally focussed on severity levels, but in the past
decade, evidence has increased that patients and pro-
fessionals perceive severity levels differently [37, 38]. It is
likely that patients’ assessments of symptom severity or
change are not formed by severity level alone [39], but
rather are a combination of a triad of symptom severity,
its importance in their lives and their ability to manage it
[40]. All parts of this triad require measuring and, for the
symptom of RA fatigue, this is now possible.
TABLE 4 Mean change and effect sizes, sensitivity study 3 (n= 42)
T1, mean (S.D.) T2, mean (S.D.) Mean change 95% CI
P value
(paired t-test) Effect size
BRAF-MDQ
Global (070) 42.4 (14.7) 34.6 (17.9) 7.74 12.11, 3.38 0.001 0.56
Physical (022) 16.8 (3.5) 13.9 (6.1) 2.89 4.59, 1.2 0.001 0.54
Living (021) 11.4 (5.7) 9.1 (6.1) 2.32 3.69, 0.95 0.001 0.53
Cognition (015) 8.0 (4.3) 6.8 (4.4) 1.20 2.34, 0.05 0.041 0.33
Emotion (012) 6.2 (3.6) 4.8 (3.3) 1.34 2.34, 0.34 0.010 0.42
BRAF-NRS
Severity (010) 7.2 (1.7) 5.9 (2.5) 1.25 2.07, 0.43 0.004 0.47
Effect (010) 7.0 (2.3) 5.8 (2.6) 1.25 2.09, 0.41 0.005 0.46
Coping (010)a 5.6 (2.2) 5.4 (2.5) 0.13 1.03, 0.77 0.771 0.05
SF-36 VT (0100)a 29.3 (17.9) 37.0 (21.0) 7.68 0.48, 14.88 0.037 0.34
FACIT-F (052)a 19.3 (9.8) 24.9 (12.8) 5.57 2.43, 8.71 0.001 0.55
POMS (028) 19.1 (6.1) 15.7 (7.7) 3.46 5.59, 1.32 0.002 0.53
MAF (150) 35.9 (8.9) 30.5 (10.1) 5.34 8.65, 2.04 0.002 0.57
aHigher scores indicate better outcome.
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The provisional exploration of MCIDs suggested that a
greater change in fatigue was required to trigger a per-
ceived improvement on the transition question than was
needed to perceive fatigue worsening (BRAF-MDQ 17.5%
vs 6.1% or 7.43 vs +2.58). Similar differences in MCID
between improvement and worsening have also been
reported in the measurement of disease activity [41].
The sensitivity study was not powered for calculation of
MCID, therefore these provisional findings need further
exploration in a larger data set. In addition, fatigue was
not necessarily the primary clinical issue for the partici-
pants receiving the single i.m. injection of high-dose
glucocorticoids. It is possible that the findings would
have been enhanced if participants had been recruited
because of fatigue rather than because of an inflammatory
flare. Nonetheless, they suggest that the mean BRAF
scores for better, same and worse fatigue on the transition
question are in the expected direction and pattern.
A strength of these studies is that the larger number of
PROMs, administered in different orders at each time
point, meant that it was unlikely that patients would
recall their previous answers.
The BRAFs performed as well as three of the existing
comparator fatigue PROMs and better than the SF-36
vitality subscale. In addition, two of the existing scales
had a large proportion of missing data, making them un-
usable, similar to rates reported in other studies [12, 42].
Furthermore, the additional value of the BRAFs beyond
the existing fatigue scales is that for the first time they
allow the measurement of different dimensions of RA fa-
tigue and to separate measurement of fatigue severity
from fatigue effect and fatigue coping. Evidence of valid-
ation for PROMs is never completed but depends on
building a substantial body of evidence from a number
of sources. The BRAFs have been translated into 34 lan-
guages and are currently being used in at least four
multinational RCTs, and it is anticipated this will contribute
further information to the body of evidence on validity,
reliability and sensitivity.
Conclusions
These studies provide evidence contributing to the reli-
ability (stability) and sensitivity of the BRAFs. It is now
possible to measure four different dimensions of RA fa-
tigue (such as physical and cognitive fatigue) separately,
as well as distinguishing between fatigue severity, coping
and effect. In future we should therefore be able to assess
which components of an individual patient’s fatigue are
most troublesome, so that we can move toward develop-
ing and testing a range of interventions targeted appropri-
ately to those individual needs.
Rheumatology key messages
. BRAFs are validated PROMs designed in collabor-
ation with patients.
. BRAFs were reliable in stable patients and sensitive
to change after intervention.
. In RA, coping with fatigue is distinct from severity
and effect, requiring separate measurement.
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